Tarig Fadelelmoula, 2020;4(3):547–554.
https://doi.org/10.24911/IJMDC.51-1576331607

REVIEW ARTICLE

Extracorporeal membrane oxygenation therapy in adult patients: a narrative review of literature

Tarig Fadelelmoula[1*]

ABSTRACT

Extracorporeal membrane oxygenation (ECMO) therapy has been around since the 1970s and has completely changed how critical physicians view supportive therapy patient's care. ECMO provides cardio-respiratory support when other therapies fail. In ECMO, different arrangements of cannulae shunt blood to circulate through the machine, and hence oxygenated outside the body. Extracorporeal membrane oxygenation configurations can be simple like Veno-venous and Arteriovenous venous or complex like hybrid cannulation modes and Veno-pulmonary artery configurations. ECMO is a lifesaving therapy but it is not without complications, patients' selection should be careful, and monitoring during the treatment is crucial. This review paper focuses on the definition, principles, types, and practical applications of ECMO therapy.

Keywords: Acute respiratory distress syndrome, cardiogenic shock, extracorporeal membrane oxygenation, hybrid, cannulation, membrane lung, venovenous extracorporeal membrane oxygenation, veno-arterial extracorporeal membrane oxygenation, clinical outcomes.

Introduction and Background

Extracorporeal membrane oxygenation (ECMO) therapy has been in the clinical practice since the 1970s and has completely changed how critical care physicians view supportive therapy patients' care. ECMO provides temporary cardiorespiratory support to critically ill patients when maximal conventional support proved to be ineffective [1]. It works by bringing the blood to the inside of the machine where it will be near oxygen allowing gas exchange across a thin membrane (Figure 1) [2]. The classical ECMO circuit consists of a blood pump, membrane oxygenator, drainage and return cannulae, flow and pressure sensors, heat exchanger for cooling or heating the blood, and arterial and venous access points for the collection of blood in the circuit (Figure 1) [2]. It is used for more than 50 years as salvage therapy for patients with severe cardiopulmonary failure that is refractory to conventional treatment [3]. In 1972, reported the first successful use of long-term ECMO in an adult with the newly described acute respiratory distress syndrome (ARDS) was reported [4]. The focus of this paper is to provide a concise review of the best clinical practices for the utilization of ECMO in managing pulmonary and cardiovascular failures.

The Review

Indications

There are four main categories of indications for the use of ECMO: hypoxemic respiratory failure, hypercapnic respiratory failure, cardiogenic shock, and cardiac arrest [5–7].

Contraindications

The Extracorporeal Life Support Organization (ELSO) consensus defines that, there is no absolute contraindication to the use of ECMO, but to reduce the risk and to increase the benefit of ECMO, each patient

Correspondence to: Tarig Fadelelmoula
*Department of Respiratory Care, College of Applied Sciences, Almaarefa University, Riyadh, Saudi Arabia.
Email: eltarig70@hotmail.com
Full list of author information is available at the end of the article.
Received: 14 December 2019 | **Accepted:** 09 February 2020

© IJMDC. https://www.ijmdc.com

DISCOVER




Figure 1. *Oxygenator and oxygenation membrane. Once the cannulation of the patient is completed and the extracorporeal membrane oxygenation circuit is established, the patient's blood is pumped to the oxygenator. The oxygenator consists of a container with two chambers separated by a semipermeable membrane - the oxygenation membrane. While the patient's blood flows through one chamber, a gas mixture, called fresh gas flow, flows through the other. It is through the oxygenation membrane that gas diffusion occurs between the patient's blood and the fresh gas flow, allowing for the oxygenation of venous blood and the removal of carbon dioxide. The composition of the gas mixture in the fresh gas flow is determined by adjusting the inspired fraction of oxygen in the gas mixer.* O_2*—oxygen;* CO_2*—carbon dioxide.*

should have individualized ECMO support and risk assessment plans [8]. However, there are situations in which the benefit of the ECMO is questionable and considered as a contraindication to its use. The main contraindications include uncontrolled active hemorrhage, incurable cancer, solid organ transplant or immunosuppression, irreversible central nervous system dysfunction, and irreversible or end-stage heart or respiratory failure in patients who are not listed as transplant candidates [6,7].

Hazards

Although ECMO offers patients a chance of overcoming critical cardiopulmonary illnesses and improves survival, it is not without significant hazards [1].

Modalities

The ECMO circuit configurations include VV-ECMO (Figure 2) [2] or as VA-ECMO (Figure 3) [9,10]. In both ECMO modalities, an access route is required for drainage, as well as an access route for the return of the blood to the patient (Figures 2 and 3) [2]. Usually, venous accesses are performed percutaneously and are ultrasound guided. The arterial accesses can be performed percutaneously or surgically [8].

VV-ECMO

The principle of VV-ECMO is that the membrane lung (oxygenator) is arranged sequentially with the normal lungs rather than in parallel like with cardiopulmonary bypass (Figure 2) [2]. Therefore, the lungs do not have to exert high effort to oxygenate the blood [11]. Using a drainage cannula, blood is drained from the right atrium (RA) and after going through the membrane lung, the newly oxygenated blood is returned to the RA [12]. Because of this, the newly oxygenated blood mixes with the native venous blood and helps provide enough systemic oxygen delivery to meet metabolism needs and preserve the airway even with at rest mechanical ventilation settings. With ventilator settings placed at lower tidal volume, there is less risk of barotrauma.

VA-ECMO

In this modality of extracorporeal membrane oxygenation the drainage cannula is inserted into venous access and the return cannula into arterial access, thus, a characteristic of VA-ECMO is the exclusion or bypassing of pulmonary circulation (Figure 3) [2].




Figure 2. *Diagram of a venovenous extracorporeal membrane oxygenation circuit. Blood from the inferior vena cava is drained through a cannula in the right femoral vein. Then, the blood passes through the propulsion pump and the oxygenation membrane, returning to the venous system of the patient through the right internal jugular vein.*




Figure 3. *Diagram of a peripheral venoarterial extracorporeal membrane oxygenation circuit. The blood from the inferior vena cava is drained through a cannula in the right femoral vein. Then, the blood passes through the blood pump and the oxygenation membrane, returning to the arterial system of the patient through the left femoral artery.*

Clinical goals

By utilizing this oxygenation circuit as a supportive therapy, physicians can provide treatment that is more effective for patients with respiratory, cardiac, or cardiopulmonary failure. This is because many of those patients are also on mechanical ventilators, which need to remain at low tidal volume and lower positive end-expiratory pressure settings to prevent further destruction of an already damaged lung tissue. This is why ECMO therapy use has drastically increased [13].

Initial Setting

Setting VV-ECMO

An initial blood flow by the system of 50 ml/kg/minute of ideal body weight is suggested which is then fine-tuned to maintain the peripheral saturation of hemoglobin measured by pulse oximetry (SpO_2) at a level of more than 80% [8]. In addition to this initial value, a determinant factor for hypoxemia correction is the ratio between the system flow and native cardiac output, and system flow values of approximately 60% of cardiac output are required to ensure the desired systemic oxygenation of more than 80% is maintained.

Setting VA-ECMO

An initial blood flow by the system of 30 ml/kg/minute of ideal body weight is suggested and then is adjusted so that the central venous oxygen saturation is more than 70 % [2]. The fresh gas flow should be adjusted to maintain the blood pH at close to 7.40 and the partial pressure of carbon dioxide ($PaCO_2$) at 40 mmHg, and in a patient with $PaCO_2$ more than 50 mmHg, the reduction must be slow and gradual, not exceeding reduction values greater than 10 mmHg per hour [8]. In a patient with an indication for ECMO due to hypercapnia, it is suggested that initially the blood flow below (1 l/minute) and the fresh gas flow high (15 l/minute), with subsequent adjustment to maintain the blood pH at values at close to 7.40 and $PaCO_2$ at values close to 40 mmHg [8].

Monitoring

In addition to the routine intensive therapy care, monitoring, special aspects of ECMO parameters should be checked regularly and optimized.

Monitoring the patient

Regarding the patient-side, monitoring control of hemodynamics, gas exchange, anticoagulation status, leg perfusion, as well as neurological monitoring is of paramount importance.

Monitoring the device

In terms of device monitoring, pump flow per minute, fresh gas flow and inspiratory O_2-fraction, have to be regularly recorded. A multi-professional and interdisciplinary team of service providers and physicians well skilled in the use of the ECMO system is of extreme importance for the quality and patient-safe ECMO setting [14].

Patient Selection

Patient selection in VV-ECMO

The general indications for VV-ECMO ECMO are severe respiratory failure that is refractory to maximal efforts of conventional intensive care and estimated risk of mortality exceeding 80%. The underlying disease should be reversible or the patient should be a candidate for lung transplantation.

Patient selection in VA-ECMO

VA-ECMO is a highly effective therapy for patients with cardiogenic shock and cardiac arrest. It is also favored as a bridge therapy as various studies have shown that VA-ECMO can have a beneficial effect as a bridge-to-recovery therapy in patients with pulmonary hypertension and pulmonary embolism. VA-ECMO also has improved outcomes for post-cardiac surgery patients [15].

ECMO and ARDS

The use of ECMO for hypoxemic respiratory failure increased very rapidly in the past decade, owing to its success in the H1N1 (Swine Flu) pandemic and the CESAR trial. Although ECMO's specific role and optimal timing in ARDS, and even its effect on the pathophysiology of ARDS have not been fully described, the recently published EOLIA trial suggests that ECMO's role in the treatment algorithm for ARDS and certainly severe ARDS should be expanded. The results of the studies suggest that in cases of ARDS, often the final common pathway for lung injuries that cause severe hypoxemia, ECMO should be instituted early, before ventilator-induced lung injury (VILI) occurs and possibly even before the onset of multiple organ dysfunction syndromes [3].

ECMO in hypercapnic respiratory failure

Hypercapnic respiratory failure (HRF) is defined as chronic respiratory failure characterized by the elevated levels of carbon dioxide in the blood. The main and frequent cause of HRF is chronic obstructive pulmonary disease or long-standing obesity hypoventilation syndrome. Treating this patient, with invasive mechanical ventilation, will lead to complications like dynamic hyperinflation and elevations of intrinsic positive end-expiratory pressure (PEEP); ventilator-associated pneumonia, and impairment of aerosolized medications delivery [16,17]. Because of these expected complications, ECMO therapy is an excellent supportive therapy for HRF [15]. This has been confirmed with clinical trials, where ECMO therapy improved the prognosis of HRF patients [18].

ECMO in cardiogenic shock

ECMO has been proven to have a good clinical outcome that is comparable to outcomes seen in patients of non-fulminant myocarditis [19]. Cardiogenic shock secondary to acute myocardial infarction is also treated with VA-ECMO therapy. It offers an advantage over traditional medical therapy with inotropes and vasopressors, in that cardiac output increases without increasing the demand on the myocardial tissue. It also offers the benefit of rapid insertion, biventricular support, and lung rest in cases of simultaneous respiratory failure [15]. Early ECMO therapy initiation in patients with cardiogenic shock secondary to myocardial infarction has demonstrated improved 30-day outcomes in patients [20].

In a different study performed 2 years later, it was confirmed that patients benefited with improved 30-day outcomes and that their 1-year outcome was better with the ECMO therapy [21].

ECMO and lung transplantation

Although there is not enough data to support its usage, there has been a recent increase in the utilization of ECMO as a bridge to lung transplantation. ECMO as a bridge to transplantation is not suited for all the patients. Careful selection of candidate patients is extremely important to optimize resource utilization and provide the best opportunity for transplantation [22].

Weaning

The decision to remove ECMO support depends on the improvement of organ dysfunctions and resolution of the indication for using ECMO support for a particular patient [2].

Weaning from VV-ECMO

Weaning from VV-ECMO, due to acute, hypoxemic or hypercapnic respiratory failure, can be initiated when the patient can satisfactorily maintain gas exchange with acceptable mechanical ventilation settings (peak pressure $\leq$ 30 cmH_2O, PEEP $\leq$ 15 cmH_2O, tidal volume $\leq$ 6 ml/kg of predicted weight, RR $\leq$ 35 rpm and $FiO_2 \leq 60\%$), in combination with improved radiographic parameters and pulmonary compliance [23]. Some institutions perform a spontaneous breathing test for weaning from VV-ECMO, which consists of interrupting the fresh gas flow from the system. During the spontaneous breathing test, it is essential that the respiratory and hemodynamic parameters, such as SpO_2, RR, end-tidal carbon dioxide ($EtCO_2$), heart rate, and mean arterial pressure, have rigorous monitoring. In patients who remain stable during the autonomy test for up to 6 hours, we perform an arterial blood gas analysis. If the pH and PaO_2 are within the target range, we consider the removal of ECMO support.

Weaning from VA-ECMO

Weaning from VA-ECMO depends on the improvement of cardiac function [8]. Predictors that indicate cardiac function recovery include the maintenance of continuous arterial pulse pressure for at least 24 hours, echocardiography with evidence of recovery of systolic function (ejection fraction of the left ventricle $\geq$ 20%) and adequate arterial oxygenation [24]. The most routine approach for VA-ECMO weaning consists of the gradual and progressive reduction of the pump flow until the contribution of the circuit to oxygenation and/or cardiac output of the patient is negligible, usually with pump flow values less than than 1 l/minute, Then clamping the arterial and venous circuits for 1 to 2 minutes [24]. The hemodynamic parameters should have close monitoring, and the patient should remain stable during the spontaneous breathing test. An echocardiogram should be repeated after the ECMO circuit clamping. If the cardiac index is maintained at higher than 2.2 l/minute/m^2, with ventricular ejection fraction > 35% and the patient remains stable for at least 24 hours, VA-ECMO can be removed [24]. If there is the impossibility of VA-ECMO removal, the use of a ventricular assist device, such as bridge-to transplantation should be considered [24]. Ideally, removal of the VA-ECMO cannula should be performed 30 to 60 minutes after discontinuation of heparin [8]. The venous cannula can be removed at the bedside, and the arterial cannulae are usually removed in the operating room.

Hybrid and Complex ECMO configurations

In addition to the traditional VA and VV ECMO modes, other ECMO cannulation strategies and configurations are increasingly considered during the ECMO course [25]. Triple cannulation can be useful to improve venous drainage or combine both respiratory and circulatory support in the case of combined lung and heart dysfunction (Figure 4) [26]. Veno-Pulmonary artery cannulation is a novel modification of VV ECMO to provide respiratory support in case of right ventricular failure. For LV unloading, both surgical and percutaneous procedures are available. The combination of VA ECMO with intra-aortic balloon pump (IABP), Impella, or Tandem-Heart may also be valuable therapies to enhance effective LV or right ventricular unloading (Figure 5) [27].

Complications

Like any other therapy with vascular access device insertion, ECMO therapy can have complications. These include bleeding, deep venous thrombosis, possible stroke, and infection [28]. Other complications include intravascular catheter breaking with consequent trauma and lost or broken guidewire [29]. With the increased training and use of ultrasound imaging guidance during insertion, these complications are gradually decreasing.




Figure 4. *Different type of extracorporeal membrane oxygenation (ECMO) "hybrid" cannulation modes. (A) Veno-venous-arterial (VVA) ECMO with double venous cannulation (combination of venous access is variable) for drainage and femoral artery cannulation for perfusion. (B) Venous-arterial-venous (VAV) ECMO with single venous drainage and right femoral artery and right internal jugular vein for perfusion. (C) Veno-veno-venous-arterial (VVVA) with double-lumen cannula acting only as venous drainage and right femoral artery as perfusion; (C) veno-venous-arterio-venous (VVAV) ECMO with double venous cannulation and right femoral artery and vein as perfusion; and (D) VVVA with triple venous drainage and femoral artery as perfusion.*




Figure 5. *Percutaneous mechanical circulatory support devices, such as IABP (A), Impella (B) or Tandem-Heart (C), in combination with veno-arterial ECMO. ECMO, extracorporeal membrane oxygenation; VA, veno-arterial.*

Conclusions

The literature reviewed in this paper focuses on the deferent aspects of extracorporeal membrane oxygenation therapy. It goes into detail regarding the principle, indication, contraindication, configurations, vascular access, and complications. This is a review paper to allow busy, practicing physicians, respiratory therapists, and perfusionists to have a cumulative view of the current situation regarding this lifesaving therapy.

List of Abbreviations

ARDS	Acute respiratory distress syndrome
ELSO	Extracorporeal Life Support Organization

HRF	Hypercapnic respiratory failure
IABP	Intra-aortic balloon pump
PEEP	Positive end-expiratory pressure
RA	Right atrium
VVVA	Veno-veno-venous-arterial

Conflict of interest
The author declares that there is no conflict of interest regarding the publication of this article.

Funding
None.

Consent for publication
Not applicable.

Ethical approval
Not applicable.

Author details
Tarig Fadelelmoula
1. Department of Respiratory Care, College of Applied Sciences, Almaarefa University, Riyadh, Saudi Arabia

References

1. Combes A, Brodie D, Chen YS, Fan E, Henriques JP, Hodgson C, et al. The ICM research agenda on extracorporeal life support. Intensive Care Med. 2017;43(9):1306–18. https://doi.org/10.1007/s00134-017-4803-3
2. Squiers JJ, Lima B, DiMaio JM. Contemporary extracorporeal membrane oxygenation therapy in adults: fundamental principles and systematic review of the evidence. J Thorac Cardiovasc Surg. 2016;152(1):20–32. https://doi.org/10.1016/j.jtcvs.2016.02.067
3. Patel B, Chatterjee S, Davignon S, Herlihy JP. Extracorporeal membrane oxygenation as rescue therapy for severe hypoxemic respiratory failure. J Thorac Dis. 2019;11(S14 Suppl 14):S1688–97. https://doi.org/10.21037/jtd.2019.05.73
4. Hill JD, O'Brien TG, Murray JJ, Dontigny L, Bramson ML, Osborn JJ, et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. N Engl J Med. 1972;286(12):629–34. https://doi.org/10.1056/NEJM197203232861204
5. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomized controlled trial [Erratum in Lancet. 2009; 374] [9698]. Lancet. 2009;374(9698):1351–63. https://doi.org/10.1016/S0140-6736(09)61069-2
6. MacLaren G, Combes A, Bartlett RH. Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med. 2012;38(2):210–20. https://doi.org/10.1007/s00134-011-2439-2
7. Kulkarni T, Sharma NS, Diaz-Guzman E. Extracorporeal membrane oxygenation in adults: A practical guide for internists. Cleve Clin J Med. 2016;83(5):373–84. https://doi.org/10.3949/ccjm.83a.15021
8. Extracorporeal Life Support Organization (ELSO). ELSO Guidelines for Cardiopulmonary extracorporeal life support. Version 1.3 Nov 2013 [Internet]. Ann Arbor, MI: ELSO; 2013 [cited 2019 Dec 14].
9. Allen S, Holena D, McCunn M, Kohl B, Sarani B. A review of the fundamental principles and evidence base in the use of extracorporeal membrane oxygenation (ECMO) in critically ill adult patients. J Intensive Care Med. 2011;26(1):13–26. https://doi.org/10.1177/0885066610384061
10. Reeb J, Olland A, Renaud S, Lejay A, Santelmo N, Massard G, et al. Vascular access for extracorporeal life support: tips and tricks. J Thorac Dis. 2016;8(S4 Suppl 4):S353–63. https://doi.org/10.21037/jtd.2016.04.42
11. Banfi C, Pozzi M, Siegenthaler N, Brunner ME, Tassaux D, Obadia JF, et al. Veno-venous extracorporeal membrane oxygenation: cannulation techniques. J Thorac Dis. 2016;8(12):3762–73. https://doi.org/10.21037/jtd.2016.12.88
12. Delnoij TS, Driessen R, Sharma AS, Bouman EA, Strauch U, Roekaerts PM. Venovenous extracorporeal membrane oxygenation in intractable pulmonary insufficiency: practical issues and future directions. BioMed Res Int. 2016;2016:9367464. https://doi.org/10.1155/2016/9367464
13. Extracorporeal Membrane Oxygenation (ECMO); 2019 [cited 2019 Dec 14]. Available from: https://www.ucsfhealth.org/treatments/extracorporeal_mechanical_oxygenation/
14. Merkle J, Azizov F, Fatullayev J, Weber C, Maier J, Eghbalzadeh K, et al. Monitoring of adult patient on venoarterial extracorporeal membrane oxygenation in intensive care medicine. J Thorac Dis. 2019;11(S6 Suppl 6):S946–56. https://doi.org/10.21037/jtd.2018.10.29
15. Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25 25 Pt A):2769–78. https://doi.org/10.1016/j.jacc.2014.03.046
16. Ai-Ping C, Lee KH, Lim TK. In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest. 2005;128(2):518–24. https://doi.org/10.1378/chest.128.2.518
17. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, et al.; Outcomerea Study Group. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011;184(10):1133–9. https://doi.org/10.1164/rccm.201105-0867OC
18. Conrad SA, Zwischenberger JB, Grier LR, Alpard SK, Bidani A. Total extracorporeal arteriovenous carbon dioxide removal in acute respiratory failure: a phase I clinical study. Intensive Care Med. 2001;27(8):1340–51. https://doi.org/10.1007/s001340100993
19. Asaumi Y, Yasuda S, Morii I, Kakuchi H, Otsuka Y, Kawamura A, et al. Favourable clinical outcome in patients with cardiogenic shock due to fulminant myocarditis supported by percutaneous extracorporeal membrane oxygenation. Eur Heart J. 2005;26(20):2185–92. https://doi.org/10.1093/eurheartj/ehi411
20. Sheu JJ, Tsai TH, Lee FY, Fang HY, Sun CK, Leu S, et al. Early extracorporeal membrane oxygenator-assisted primary

percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med. 2010;38(9):1810–7. https://doi.org/10.1097/CCM.0b013e3181e8acf7

21. Tsao NW, Shih CM, Yeh JS, Kao YT, Hsieh MH, Ou KL, et al. Extracorporeal membrane oxygenation-assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock. J Crit Care. 2012;27(5):530.e1–11. https://doi.org/10.1016/j.jcrc.2012.02.012
22. Sharma NS, Hartwig MG, Hayes D Jr. Extracorporeal membrane oxygenation in the pre and post lung transplant period. Ann Transl Med. 2017;5(4):74. https://doi.org/10.21037/atm.2017.02.09
23. Peek GJ, Clemens F, Elbourne D, Firmin R, Hardy P, Hibbert C, et al. CESAR: conventional ventilatory support vs extracorporeal membrane oxygenation for severe adult respiratory failure. BMC Health Serv Res. 2006;6(1):163. https://doi.org/10.1186/1472-6963-6-163
24. Combes A, Leprince P, Luyt CE, Bonnet N, Trouillet JL, Léger P, et al. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med. 2008;36(5):1404–1. https://doi.org/10.1097/CCM.0b013e31816f7cf7
25. Sorokin V, MacLaren G, Vidanapathirana PC, Delnoij T, Lorusso R. Choosing the appropriate configuration and cannulation strategies for extracorporeal membrane oxygenation: the potential dynamic process of organ support and importance of hybrid modes. Eur J Heart Fail. 2017;19 Suppl 2:75–83. https://doi.org/10.1002/ejhf.849
26. Brasseur A, Scolletta S, Lorusso R, Taccone FS. Hybrid extracorporeal membrane oxygenation. J Thorac Dis. 2018;10(S5 Suppl 5):S707–15. https://doi.org/10.21037/jtd.2018.03.84
27. Meani P, Gelsomino S, Natour E, Johnson DM, Rocca HB, Pappalardo F, et al. Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature. Eur J Heart Fail. 2017;19 Suppl 2:84–91. https://doi.org/10.1002/ejhf.850
28. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. 2013;15(3):172–8.
29. Clement KC, Fiser RT, Fiser WP, Chipman CW, Taylor BJ, Heulitt MJ, et al. Single-institution experience with interhospital extracorporeal membrane oxygenation transport: a descriptive study. Pediatr Crit Care Med. 2010;11(4):509–13.